Antwerp (Belgium)/ France — Biolam and Gimv today announce an important step on Biolam’s growth path. Follo­wing the rapid and successful deve­lo­p­ment of the group, which combi­nes orga­nic and exter­nal growth, Gimv is selling its shares in Biolam to the foun­ding team, which is supported by private inves­tors. The foun­ders, manage­ment and their new part­ners will conti­nue to focus on quality of service and care and expan­sion in France.

In 2019, Gimv acqui­red a stake with Daniel Attias in Biolam (www.groupebiolam.fr), an emer­ging group of clini­cal test­ing labo­ra­to­ries in the city of Amiens. The origi­nal plan, deve­lo­ped with Daniel Attias, aimed to create a leading player in the Hauts-de-France region in terms of size, clini­cal perfor­mance and level of service.

From the begin­ning, Biolam has grown very quickly thanks to a combi­na­tion of estab­li­shing labo­ra­to­ries in under­ser­ved loca­ti­ons, which is an important prere­qui­site for acces­si­ble quality care, and stra­te­gic acqui­si­ti­ons. In paral­lel, the Group conti­nuously inves­ted in staff, care orga­niza­tion, diagno­stic equip­ment and IT back­bone to support its ambi­tious medi­cal project. These efforts have enab­led Biolam to become a leading labo­ra­tory group in the Hauts-de-France and Normandy region, with a solid foun­da­tion for contin­ued success.

The company curr­ently opera­tes a network of more than 30 labo­ra­to­ries with 4 tech­ni­cal plat­forms and has an exten­sive pipe­line of active acqui­si­tion targets. Since Gimv’s invest­ment in 2019, Biolam has signed 7 addi­tio­nal acqui­si­ti­ons and built a leading and high-quality diagno­stics organization.

The tran­sac­tion announ­ced today will streng­then the company’s relent­less focus on quality service and care, as well as expan­sion in its regi­ons. The manage­ment team, toge­ther with its new part­ners, will conti­nue to invest in its orga­niza­tion while expan­ding its labo­ra­tory network to create an even better diagno­stics company for all stakeholders.

The tran­sac­tion has no mate­rial impact on the net asset value of Gimv as of Septem­ber 30, 2022. Further finan­cial details will not be disclosed.

Gautier Lefeb­vre, Part­ner at Gimv, and Kevin Klein, Prin­ci­pal at Gimv., state, “We are very proud to have part­ne­red with Biolam and Daniel Attias on the company’s growth stra­tegy, which has always put the quality of diagno­stics and level of service to physi­ci­ans first, espe­ci­ally during the pande­mic. From the begin­ning, we were perfectly aligned with the manage­ment team, resul­ting in an opti­mal ability to build the busi­ness and seize growth oppor­tu­ni­ties. We would like to thank the manage­ment of Biolam for their successful and excel­lent coope­ra­tion and wish them — toge­ther with their new part­ners — all the best for their further growth.”

Daniel Attias, Chair­man of the Biolam Group, says, “We have excee­ded the goals we origi­nally set with the Gimv team, which is a sign of very effec­tive colla­bo­ra­tion. We are grateful for the successful part­ner­ship with Gimv that has enab­led Biolam’s evolu­tion into an estab­lished and leading labo­ra­tory group with a solid foun­da­tion for the next phase of growth, and we look forward to conti­nuing to grow with our new partners.”

Trans­la­ted with www.DeepL.com/Translator (free version)